MINT-RIVASTIGMINE CAPSULE
Land: Kanada
Språk: engelska
Källa: Health Canada
Produktens egenskaper
(SPC)
22-12-2016
Vissa dokument för denna produkt är för närvarande inte tillgängliga, du kan skicka en begäran till vår kundservice och vi kommer att meddela dig så snart vi kan få dem.
Skicka förfrågan.
Skicka förfrågan.
Aktiva substanser:
RIVASTIGMINE (RIVASTIGMINE HYDROGEN TARTRATE)
Tillgänglig från:
MINT PHARMACEUTICALS INC
ATC-kod:
N06DA03
INN (International namn):
RIVASTIGMINE
Dos:
4.5MG
Läkemedelsform:
CAPSULE
Sammansättning:
RIVASTIGMINE (RIVASTIGMINE HYDROGEN TARTRATE) 4.5MG
Administreringssätt:
ORAL
Enheter i paketet:
56/100
Receptbelagda typ:
Prescription
Terapiområde:
PARASYMPATHOMEMETIC (CHOLINERGIC) AGENTS
Produktsammanfattning:
Active ingredient group (AIG) number: 0140521003; AHFS:
Bemyndigande status:
CANCELLED POST MARKET
Tillstånd datum:
2017-06-19
Produktens egenskaper
PRODUCT MONOGRAPH
PR
MINT-RIVASTIGMINE
1.5 mg, 3 mg, 4.5 mg, 6 mg Rivastigmine
(supplied as Rivastigmine Hydrogen Tartrate)
Capsules
Mint Standard
Cholinesterase Inhibitor
Mint Pharmaceuticals Inc. Date of Revision: December 22, 2016
1093 Meyerside Drive, Unit 1
Mississauga, Ontario
L5T 1J6
Submission Control No: 200803
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
...................................................... 3
SUMMARY PRODUCT INFORMATION
......................................................................
3
INDICATIONS AND CLINICAL USE
............................................................................
3
CONTRAINDICATIONS
..............................................................................................
4
WARNINGS AND PRECAUTIONS
..............................................................................
4
ADVERSE REACTIONS
............................................................................................
11
DRUG INTERACTIONS
............................................................................................
25
DOSAGE AND ADMINISTRATION
...........................................................................
26
OVERDOSAGE
.........................................................................................................
28
ACTION AND CLINICAL PHARMACOLOGY
............................................................ 29
STORAGE AND STABILITY
......................................................................................
32
DOSAGE FORMS, COMPOSITION AND PACKAGING
........................................... 32
PART II: SCIENTIFIC INFORMATION
..........................................................................
33
PHARMACEUTICAL INFORMATION
........................................................................
33
CLINICAL TRIALS
.....................................................................................................
34
DETAILED PHARMACOLOGY
..........................................................................
Läs hela dokumentet
